Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial investigating evofosfamide in combination with both CTLA-4 and PD-1 blockade in patients with castration-resistant prostate cancer (CRPC), pancreatic ductal adenocarcinoma (PDAC) and HPV-negative head and neck cancer (HNSCC)

Next Previous
X
Search
Trial Profile

A Phase 2 clinical trial investigating evofosfamide in combination with both CTLA-4 and PD-1 blockade in patients with castration-resistant prostate cancer (CRPC), pancreatic ductal adenocarcinoma (PDAC) and HPV-negative head and neck cancer (HNSCC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary)
  • Indications Head and neck cancer; Pancreatic cancer; Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Feb 2022 According to an IMMUNOGENESIS media release, this trial is expected to begin in 2022.
    • 17 Dec 2020 New trial record
    • 09 Dec 2020 According to an IMMUNOGENESIS media release, this trial is supported by data from a Phase 1 trial (NCT03098160), and this trial will be led by David S. Hong, M.D., Professor of Investigational Cancer Therapeutics at MD Anderson.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top